oxonic acid has been researched along with Squamous Cell Carcinoma of Head and Neck in 18 studies
Oxonic Acid: Antagonist of urate oxidase.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage III, IVA, or IVB LAHNSCC were enrolled in this study to evaluate the efficacy of S-1 compared with UFT as adjuvant chemotherapy after curative CRT in the ACTS-HNC study." | 2.87 | Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study. ( Beppu, T; Fujii, M; Hanamure, Y; Hasegawa, Y; Higaki, Y; Iwae, S; Kawabata, K; Kohno, N; Kubota, A; Nagahara, K; Nakatani, E; Nakatani, H; Taguchi, T; Takemura, H; Terada, T; Teramukai, S; Tomita, K; Tsukahara, K; Yoshino, K, 2018) |
| "Eligible patients had T1b or T2 glottic squamous cell carcinomas." | 2.80 | Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. ( Fujimoto, Y; Hiramatsu, M; Itoh, J; Itoh, Y; Kawamura, M; Kimura, K; Kubota, S; Naganawa, S; Nakahara, R; Okada, T; Shibata, T, 2015) |
| " We analyzed the clinical response, survival rate, acute adverse events, and late swallowing toxicity." | 1.51 | Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma. ( Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019) |
| "The involvement of S-1 chemotherapy in ATLL development suggests that a test for HTLV-1 antibody should be performed before treatment and that S-1 should not be administered in HTLV-1 positive patients with head and neck carcinoma." | 1.46 | Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy. ( Kurono, Y; Matushita, K; Nagano, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (88.89) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Imamura, Y | 1 |
| Kiyota, N | 2 |
| Ogawa, G | 1 |
| Akimoto, T | 2 |
| Fujii, M | 4 |
| Hanai, N | 1 |
| Iwae, S | 4 |
| Monden, N | 2 |
| Matsuura, K | 2 |
| Onozawa, Y | 2 |
| Hayashi, R | 2 |
| Tahara, M | 2 |
| Yoshida, R | 1 |
| Nagata, M | 1 |
| Hirosue, A | 1 |
| Kawahara, K | 1 |
| Nakamoto, M | 1 |
| Hirayama, M | 1 |
| Takahashi, N | 1 |
| Matsuoka, Y | 1 |
| Sakata, J | 1 |
| Nakashima, H | 1 |
| Arita, H | 1 |
| Hiraki, A | 1 |
| Shinohara, M | 1 |
| Kikuchi, K | 1 |
| Nakayama, H | 1 |
| Kubota, A | 3 |
| Nakatani, E | 1 |
| Tsukahara, K | 2 |
| Hasegawa, Y | 3 |
| Takemura, H | 2 |
| Terada, T | 2 |
| Taguchi, T | 2 |
| Nagahara, K | 2 |
| Nakatani, H | 2 |
| Yoshino, K | 2 |
| Higaki, Y | 2 |
| Beppu, T | 2 |
| Hanamure, Y | 2 |
| Tomita, K | 2 |
| Kohno, N | 4 |
| Kawabata, K | 2 |
| Teramukai, S | 2 |
| Wakasaki, T | 1 |
| Yasumatsu, R | 2 |
| Uchi, R | 1 |
| Taura, M | 1 |
| Matsuo, M | 1 |
| Komune, N | 1 |
| Nakagawa, T | 2 |
| Okuda, H | 1 |
| Ohnishi, M | 1 |
| Takahashi, H | 1 |
| Takagi, C | 1 |
| Takada, N | 1 |
| Ohashi, T | 1 |
| Hoshikawa, H | 1 |
| Kishino, T | 1 |
| Mori, T | 1 |
| Indo, K | 1 |
| Inamoto, R | 1 |
| Akiyama, K | 1 |
| Miyashita, T | 1 |
| Mori, N | 1 |
| Fukushima, M | 1 |
| Mizusawa, J | 1 |
| Nakamura, K | 1 |
| Fujii, H | 1 |
| Homma, A | 1 |
| Fukuda, H | 1 |
| Kimura, K | 1 |
| Itoh, Y | 1 |
| Okada, T | 1 |
| Nakahara, R | 1 |
| Kawamura, M | 1 |
| Kubota, S | 1 |
| Itoh, J | 1 |
| Hiramatsu, M | 1 |
| Fujimoto, Y | 1 |
| Shibata, T | 1 |
| Naganawa, S | 1 |
| Hirai, M | 1 |
| Orita, Y | 1 |
| Takao, S | 1 |
| Tachibana, T | 1 |
| Marunaka, H | 1 |
| Makihara, S | 1 |
| Miki, K | 1 |
| Noyama, Y | 1 |
| Fuji, S | 1 |
| Torigoe, A | 1 |
| Sato, Y | 1 |
| Nishizaki, K | 1 |
| Nakashima, T | 1 |
| Sato, M | 1 |
| Nakano, T | 1 |
| Kogo, R | 1 |
| Hashimoto, K | 1 |
| Sawatsubashi, M | 1 |
| Nagano, H | 1 |
| Kurono, Y | 1 |
| Matushita, K | 1 |
| Yoon, DH | 1 |
| Cho, Y | 1 |
| Kim, SY | 1 |
| Nam, SY | 1 |
| Choi, SH | 1 |
| Roh, JL | 1 |
| Lee, SW | 1 |
| Song, SY | 1 |
| Lee, JH | 1 |
| Kim, JS | 1 |
| Cho, KJ | 1 |
| Kim, SB | 1 |
| Kogashiwa, Y | 2 |
| Yamauchi, K | 1 |
| Nagafuji, H | 2 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Furusaka, T | 1 |
| Tanaka, A | 1 |
| Matsuda, H | 1 |
| Ikeda, M | 1 |
| Kim, HS | 2 |
| Kim, HR | 1 |
| Kim, GM | 1 |
| Koh, YW | 1 |
| Kim, SH | 1 |
| Choi, EC | 1 |
| Hong, YK | 1 |
| Sung, JH | 1 |
| Kim, SM | 1 |
| Kim, JH | 1 |
| Cho, BC | 1 |
| Yamamoto, Y | 1 |
| Nakai, N | 1 |
| Wakabayashi, Y | 1 |
| Okuzawa, Y | 1 |
| Asai, J | 1 |
| Takenaka, H | 1 |
| Katoh, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study[NCT00336947] | Phase 3 | 500 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for oxonic acid and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1).
Topics: Adult; Aged; Anemia; Chemoradiotherapy; Cisplatin; Deglutition Disorders; Drug Combinations; Female; | 2019 |
Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2018 |
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Head and N | 2015 |
Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Fem | 2015 |
How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Sq | 2015 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Feasibility of concurrent chemoradiotherapy with S-1 administered on alternate days for elderly patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2012 |
10 other studies available for oxonic acid and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2020 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2020 |
Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2019 |
Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2015 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 2011 |
Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemother | 2011 |
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2012 |
A case of advanced cutaneous squamous cell carcinoma of the lower eyelid that was successfully treated with tegafur-gimeracil-oteracil potassium monotherapy.
Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2012 |